SCHEDULE: Kingdon Capital Management Discloses enVVeno Medical Stake

Kingdon Capital Management, L.L.C. and affiliated entities have reported beneficial ownership of 5.5% of enVVeno Medical Corporation's common stock as of March 31, 2026.

Summary

• Kingdon Capital Management, L.L.C., along with M. Kingdon Offshore Master Fund L.P., Kingdon GP, LLC, and Mark Kingdon, have jointly filed a Schedule 13G, indicating their beneficial ownership of enVVeno Medical Corporation's common stock.
• The filing, dated May 15, 2026, reports that these entities collectively beneficially own 36,166 shares of enVVeno Medical Corporation's common stock.
• This ownership stake represents 5.5% of the class of securities.
• All reported securities are directly owned by advisory clients of Kingdon Capital Management, L.L.C., with M. Kingdon Offshore Master Fund L.P. being the only advisory client that may be deemed to beneficially own more than 5% of the common stock.
• Mark Kingdon is identified as a control person for Kingdon Capital Management, L.L.C.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a standard disclosure of beneficial ownership without specific commentary on the company's performance or future prospects.

Positives

• Significant stake disclosed by a notable investment management firm, potentially indicating confidence in the company's future.
• Clear reporting of beneficial ownership, providing transparency to the market.

Risks

• Potential for increased selling pressure if Kingdon Capital Management decides to divest its stake.
• The filing does not provide specific reasons for the investment, leaving the strategic intent open to interpretation.

Future Outlook

No specific forward-looking statements or guidance were provided in this filing, as it is a disclosure of beneficial ownership.

Management Comments

• Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his, her or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes. This disclosure by Kingdon Capital Management suggests a strategic interest in enVVeno Medical Corporation, which could be a precursor to further investment or activism.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant ownership, potentially influencing market perception and trading activity.
• Management: May face increased scrutiny or engagement from Kingdon Capital Management regarding corporate strategy and performance.

Next Steps

• Monitor future filings from Kingdon Capital Management for any changes in their stake.
• Observe enVVeno Medical Corporation's strategic developments and financial performance for insights into the rationale behind this investment.

Key Dates

Recommendation

This filing indicates a significant stake by an institutional investor, which could be positive, but without further context on the company's performance or the investor's specific strategy, a 'hold' recommendation is prudent. Investors should monitor for further developments.

Keywords

Schedule 13G, enVVeno Medical Corporation, Kingdon Capital Management, beneficial ownership, common stock, SEC filing, investment management